CASI Pharmaceuticals Reports Q1 2025 Results and Asset Divestiture in China

CASI Pharmaceuticals ( (CASI) ) just unveiled an update.

On May 16, 2025, CASI Pharmaceuticals announced its first quarter 2025 business and financial results, highlighting an 82% increase in revenue to $6.2 million compared to the previous year, attributed to its commercial strategy. The company also reported a definitive agreement to sell certain assets in China to Kaixin Pharmaceuticals for $20 million, aiming to focus on its core priorities and enhance long-term value for stakeholders.

The most recent analyst rating on (CASI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.

Spark’s Take on CASI Stock

According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.

CASI Pharmaceuticals faces substantial financial difficulties, with declining revenues and increasing losses, reflected in a low financial performance score. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings and lack of dividends. These factors contribute to a low overall stock score, highlighting the need for significant improvements in operational efficiency and revenue growth.

To see Spark’s full report on CASI stock, click here.

More about CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and globally. The company specializes in hematology oncology therapeutics, organ transplant rejection, autoimmune disease treatments, and other unmet medical needs, leveraging its China-based regulatory and commercial competencies.

Average Trading Volume: 9,470

Technical Sentiment Signal: Sell

Current Market Cap: $29.59M

For an in-depth examination of CASI stock, go to TipRanks’ Stock Analysis page.